Get started
Author

Natalia Manilo

A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry
2017 · Bente Glintborg, Inge Juul Sørensen, et al. · Annals of the Rheumatic Diseases · 247
To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry
2018 · Bente Glintborg, Anne Gitte Loft, et al. · Annals of the Rheumatic Diseases · 153
PDF
Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry
2012 · Bente Glintborg, Mikkel Østergaard, et al. · Annals of the Rheumatic Diseases · 149
Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial
2013 · Kim Hørslev-Petersen, Merete Lund Hetland, et al. · Annals of the Rheumatic Diseases · 116
PDF
Validity and completeness of rheumatoid arthritis diagnoses in the nationwide DANBIO clinical register and the Danish National Patient Registry
2017 · Else Helene Ibfelt, Jan Sørensen, et al. · Clinical Epidemiology · 93
PDF
Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in routine care – 2-year outcomes and predictors
2018 · Cecilie Heegaard Brahe, Simon Krabbe, et al. · Lara D. Veeken · 42
Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with psoriatic arthritis: results from the nationwide registries DANBIO and ICEBIO
2014 · B. Glintborg, B. Gudbjornsson, et al. · Lara D. Veeken · 38
Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial
2021 · Hafsah Nabi, Stylianos Georgiadis, et al. · Annals of the Rheumatic Diseases · 33
Doppler ultrasound predicts successful discontinuation of biological DMARDs in rheumatoid arthritis patients in clinical remission
2021 · Lene Terslev, Cecilie Heegaard Brahe, et al. · Lara D. Veeken · 25
FRI0190 Clinical outcomes from a nationwide non-medical switch from originator to biosimilar etanercept in patients with inflammatory arthritis after 5 months follow-up. results from the danbio registry
2017 · B Glintborg, IJ Sørensen, et al. · Annals of the Rheumatic Diseases · 23
PDF
One-Year Clinical Outcomes in 1623 Patients with Inflammatory Arthritis Who Switched from Originator to Biosimilar Etanercept:an Observational Study from the Danish Danbio Registry
2017 · Glintborg, Bente, Omerovic, Emina, et al. · University of Southern Denmark Research Portal (University of Southern Denmark) · 15
Association between MRI findings and patient‐reported outcomes in patients with rheumatoid arthritis in clinical remission and at relapse
2020 · Daniel Glinatsi, Cecilie H. Brahe, et al. · International Journal of Rheumatic Diseases · 14
Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry
2022 · Hafsah Nabi, Oliver Hendricks, et al. · RMD Open · 12
PDF
Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab—a substudy of the optimized treatment algorithm in early RA (OPERA) trial
2016 · OPERA Study Group, L. M. Ørnbjerg, et al. · Clinical Rheumatology · 10
Flare during tapering of biological DMARDs in patients with rheumatoid arthritis in routine care: characteristics and predictors
2022 · L Terslev, Mikkel Ostergaard, et al. · RMD Open · 9
PDF
OP0225 Three Months' Clinical Outcomes from A Nationwide Non-Medical Switch from Originator To Biosimilar Infliximab in Patients with Inflammatory Arthritis. Results from The Danbio Registry
2016 · B. Glintborg, I. Juul Sørensen, et al. · Annals of the Rheumatic Diseases · 5
Hospital contacts due to hepatobiliary adverse events in >5000 patients with inflammatory joint disease treated with originator or biosimilar etanercept (SB4): an observational nationwide study applying linkage between DANBIO and national registries
2020 · Bente Glintborg, Stylianos Georgiadis, et al. · Annals of the Rheumatic Diseases · 4
Response to: ‘Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching’ by Cantini and Benucci
2018 · Bente Glintborg, Anne Gitte Loft, et al. · Annals of the Rheumatic Diseases · 4
FRI0103 One-year follow-up of a nationwide cohort of patients with inflammatory arthritis, who switched from originator to biosimilar etanercept, focusing on patients who switched back to originator. an observational danbio study
2018 · B. Glintborg, I.J. Sørensen, et al. · Annals of the Rheumatic Diseases · 4
PDF
OP0168 Clinical response, drug survival and predictors thereof in 432 patients with ankylosing spondylitis switching anti tumor necrosis factor α therapy: Results from the danish nationwide danbio registry
2012 · B. Glintborg, M. Østergaard, et al. · Annals of the Rheumatic Diseases · 4
THU0189 One-year treatment retention after a nationwide non-medical switch from originator to biosimilar etanercept in 2,061 patients with inflammatory arthritis followed in the danbio registry
2018 · B. Glintborg, I.J. Sørensen, et al. · Annals of the Rheumatic Diseases · 2
Op0065 Infliximab Biosimilar-to-biosimilar Switching in Patients With Inflammatory Rheumatic Diseases: Clinical Outcomes in Real-world Patients From the Danbio Registry
2022 · H. Nabi, M.L. Hetland, et al. · Annals of the Rheumatic Diseases · 1
PDF
Response to ''To switch or not to switch': the missing piece in the puzzle of biosimilar literature?' by Scherlinger et al
2020 · Bente Glintborg, Anne Gitte Loft, et al. · Annals of the Rheumatic Diseases · 1
PDF
AB0263 Agreement between Das28, Acr/eular, Sdai, Cdai and Ultrasound Remission in Patients with Rheumatoid Arthritis Receiving Biological Treatment in Routine Care
2016 · C.H. Brahe, L. Terslev, et al. · Annals of the Rheumatic Diseases · 1
Impact Of Low Infliximab Dose Regimen On Treatment Response and Drug Survival In 462 Patients With Psoriatic Arthritis:Results From The Nationwide Registries Danbio and Icebio
2013 · Glintborg, Bente, Gudbjornsson, Bjorn, et al. · VBN Forskningsportal (Aalborg Universitet) · 1
Works count: 35
Citation count: 1,006
H-index: 12
I10-index: 14
Year
Topic
Type